1. Home
  2. TMDX vs HAE Comparison

TMDX vs HAE Comparison

Compare TMDX & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TMDX

TransMedics Group Inc.

HOLD

Current Price

$78.56

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo Haemonetics Corporation

HAE

Haemonetics Corporation

HOLD

Current Price

$73.70

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TMDX
HAE
Founded
1998
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.8B
IPO Year
2019
1996

Fundamental Metrics

Financial Performance
Metric
TMDX
HAE
Price
$78.56
$73.70
Analyst Decision
Buy
Buy
Analyst Count
9
9
Target Price
$148.22
$84.13
AVG Volume (30 Days)
1.1M
1.0M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
382.18
N/A
EPS
0.20
2.05
Revenue
$605,494,000.00
$910,373,000.00
Revenue This Year
$24.25
N/A
Revenue Next Year
$18.75
$5.23
P/E Ratio
$394.55
$36.16
Revenue Growth
37.13
N/A
52 Week Low
$60.11
$47.32
52 Week High
$156.00
$87.32

Technical Indicators

Market Signals
Indicator
TMDX
HAE
Relative Strength Index (RSI) 56.11 61.31
Support Level $64.90 $48.98
Resistance Level $120.60 $86.72
Average True Range (ATR) 4.22 3.24
MACD 1.88 -0.15
Stochastic Oscillator 87.80 54.54

Price Performance

Historical Comparison
TMDX
HAE

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

About HAE Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Share on Social Networks: